Preliminary Phase 2 results in patients with acute myeloid leukemia, chronic myelomonocytic leukemia, and myelodysplastic syndrome with mutated p53 show no responses of cancer to therapy to date (Jonas et al., 2022). The gene discussed is TP53; the disease is cancer.